射频消融术（RFA）是肿瘤微创治疗的重要手段。我们已证实RFA联合免疫治疗可促进抗肿瘤疗效，但其作用机制尚未明确。预初实验发现结肠癌肝转移患者RFA治疗后外周血中肿瘤特异性DNA显著增加，同时对小鼠肿瘤治疗模型进行转录组测序分析发现，RFA治疗后胞内DNA识别受体AIM2表达上调。鉴此，本项目聚焦RFA致肿瘤相关DNA释放，刺激AIM2炎症小体形成并增强抗肿瘤免疫应答的科学问题。拟通过临床病例探究RFA治疗导致肿瘤细胞DNA释放的规律；应用动物模型探究RFA治疗后AIM2炎症小体的形成及其在增强抗肿瘤免疫反应中的作用；揭示肿瘤细胞来源DNA佐剂增强RFA治疗后抗肿瘤免疫应答的机制，旨在形成RFA联合免疫治疗肿瘤的新策略。

Radiofrequency ablation (RFA) is an important strategy for minimally invasive treatment of tumor. We have demonstrated that RFA can significantly promote antitumor immunity, but how RFA activates antitumor immune response still remains to be elucidated. In the recent study, we found that tumor specific DNA in peripheral blood was significantly increased after RFA treatment in colon cancer patients with liver metastasis. RNA-seq results revealed the enhancement of the expression of AIM2, the recognition receptor for the intracellular DNA after RFA treatment. Based on our previous studies, we propose that RFA leads to the release of tumor specific DNA from cancer cells to stimulate the formation of inflammasome of AIM2 and enhance the antitumor immune response. We aim to analyze the feature of the release of tumor specific DNA from patients treated by RFA. Then we also use the animal model to reveal the mechanism of RFA lysate inducing AIM2 inflammasome formation and enhancing the antitumor immune response.We also aim to investigate the mechanism of adjuvant tumor specific DNA in enhancing the antitumor immunity after RFA. Our study would provide a new therapeutic strategy for the combination of RFA with immunotherapy.